Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Sequential Triple Therapy With Ibrutinib, Obinutuzumab and Venetoclax in First and Second Line for Patients With Chronic Lymphocytic Leukemia

NCT03755947 is registered in ClinicalTrials.gov with Grupo Cooperativo de Hemopatías Malignas as lead sponsor.

NCT NCT03755947
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03755947 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Sequential Triple Therapy With Ibrutinib, Obinutuzumab and Venetoclax in First and Second Line for Patients With Chronic Lymphocytic Leukemia
Lead sponsor
Grupo Cooperativo de Hemopatías Malignas
Phase
Phase 2
Overall status
Completed
Start date
December 1, 2018
Completion date
February 1, 2021
Enrollment
3 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

b-cell chronic lymphocytic leukemia, b-cell chronic lymphocytic leukemia in relapse (diagnosis)